These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27668564)

  • 1. Overview of Comprehensive Hepatitis C Virus Medication Management in a State Medicaid Program.
    Lavitas P; Tesell M; Hydery T; Greenwood BC; Price M; Lenz K; Jeffrey P
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1161-6. PubMed ID: 27668564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.
    Clements KM; Clark RE; Lavitas P; Kunte P; Graham CS; O'Connell E; Lenz K; Jeffrey P
    J Manag Care Spec Pharm; 2016 Jun; 22(6):714-722b. PubMed ID: 27231798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing Access to Hepatitis C Virus Medications: A Program Model Using Patient Navigators and Specialty Pharmacy to Obtain Prior Authorization Approval.
    Vu TM; Toribio W; Riazi F; Ciprian G; Gibbs N; Giardina M; Camacho JA; Parrella K; Cambe J; Amory C; Chasan R; Sigel KM; Weiss JJ
    J Manag Care Spec Pharm; 2018 Apr; 24(4):329-333. PubMed ID: 29578854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
    Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
    J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic and utilization outcomes of medication management at a large Medicaid plan with disease management pharmacists using a novel artificial intelligence platform from 2018 to 2019: a retrospective observational study using regression methods.
    Kessler S; Desai M; McConnell W; Jai EM; Mebine P; Nguyen J; Kiroyan C; Ho D; Von Schweber E; Von Schweber L
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1186-1196. PubMed ID: 34032130
    [No Abstract]   [Full Text] [Related]  

  • 6. An Evaluation of a Multidisciplinary Pediatric Behavioral Health Medication Initiative Workgroup's Interventions on Medication Prescribing in a Population of Medicaid Patients.
    Chiara AN; Kashalikar N; Pomfret TC; Lenz K; Faber DM; Goldstein J; Clements KM; Angelini MC; Leto P; Jeffrey PL
    J Manag Care Spec Pharm; 2018 Aug; 24(8):746-751. PubMed ID: 30058981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
    Kouris G; Hydery T; Greenwood BC; Lavitas P; Price M; Clements K; Alper CJ; Lenz K; Jeffrey PL
    J Manag Care Spec Pharm; 2018 Jul; 24(7):591-597. PubMed ID: 29952708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multichannel Medication Adherence Intervention Influences Patient and Prescriber Behavior.
    Leslie RS; Gilmer T; Natarajan L; Hovell M
    J Manag Care Spec Pharm; 2016 May; 22(5):526-38. PubMed ID: 27123914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4.
    Bach TA; Zaiken K
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1437-1445. PubMed ID: 27882839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the effect of an enhanced prior authorization and management program in a United States Medicaid program on chronic hepatitis C treatment adherence and cost.
    Keast SL; Holderread B; Cothran T; Skrepnek GH
    J Am Pharm Assoc (2003); 2018; 58(5):485-491. PubMed ID: 30033127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Pharmacy-Led Hepatitis C Direct-Acting Antiviral Utilization Management at a Veterans Affairs Medical Center.
    Yang S; Britt RB; Hashem MG; Brown JN
    J Manag Care Spec Pharm; 2017 Mar; 23(3):364-369. PubMed ID: 28230455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Comprehensive Medication Review Completion Rates Using 3 Patient Outreach Models.
    Miller DE; Roane TE; Salo JA; Hardin HC
    J Manag Care Spec Pharm; 2016 Jul; 22(7):796-800. PubMed ID: 27348280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability of a new specialty pharmacy-reported measure describing completion of therapy for hepatitis C.
    Bolduc C; McCall K; Stickney K; Gelinas A; Levesque E
    J Manag Care Spec Pharm; 2021 Feb; 27(2):263-267. PubMed ID: 33506724
    [No Abstract]   [Full Text] [Related]  

  • 14. Financial Sustainability of an Oregon Rural Health, Primary Care, and Pharmacist-Run Comprehensive Medication Management Program Through Direct Medical Billing.
    Hoover ND; Turner RB; Sampson J; Pye T; Hotan T
    J Manag Care Spec Pharm; 2020 Jan; 26(1):30-34. PubMed ID: 31880232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of prescriber responses to pharmacist recommendations communicated by fax in a medication therapy management program (MTMP).
    Perera PN; Guy MC; Sweaney AM; Boesen KP
    J Manag Care Pharm; 2011 Jun; 17(5):345-54. PubMed ID: 21657804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic assessment of changes to an existing medication therapy management program of a large regional health plan.
    Peasah SK; Hammonds T; Liu Y; Campbell V; Manolis C; Good CB
    J Manag Care Spec Pharm; 2021 Feb; 27(2):147-156. PubMed ID: 33506728
    [No Abstract]   [Full Text] [Related]  

  • 17. The Influence of a Community Pharmacy Automatic Prescription Refill Program on Medicare Part D Adherence Metrics.
    Lester CA; Mott DA; Chui MA
    J Manag Care Spec Pharm; 2016 Jul; 22(7):801-7. PubMed ID: 27348281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C Direct-Acting Antiviral Treatment Selection, Treatment Failure, and Use of Drug-Drug Interactions in a State Medicaid Program.
    Keast SL; Holderread B; Cothran T; Skrepnek GH
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1261-1267. PubMed ID: 31663456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of an opioid management initiative by a state Medicaid program.
    Garcia MM; Angelini MC; Thomas T; Lenz K; Jeffrey P
    J Manag Care Spec Pharm; 2014 May; 20(5):447-54. PubMed ID: 24761816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pharmacist alternative therapy interventions in a pediatric Medicaid population.
    McNicol MC; Wheaton K; Abdel-Rasoul M; Monangai KE; Sebastian S
    J Manag Care Spec Pharm; 2023 Jul; 29(7):835-841. PubMed ID: 37404069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.